Table 1.
Incidence of reproductive tract abnormalities and SIX1 expression in mice exposed neonatally to GEN or DES1
| Age (months)2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 12 | 18 | ||||||||
| Site | Pathology | CON | GEN | DES | CON | GEN | DES | CON | GEN | DES |
| Vagina | Adenosis | 0/33 (0%) |
0/30 (0%) |
2/31 (6%) |
0/29 (0)% |
0/30 (0%) |
2/26 (8%) |
0/30 (0%) |
1/30 (3%) |
2/30 (7%) |
| Uterus | Cystic Change | 2/33 (6%) |
12/30* (40%) |
4/31 (13%) |
7/29 (24%) |
23/30* (77%) |
10/26 (38%) |
15/30 (50%) |
27/30* (90%) |
23/30 (77%) |
| Adenomyosis | 0/33 (0%) |
6/30* (20%) |
13/31* (42%) |
3/29 (10%) |
10/30 (33%) |
13/26* (50%) |
4/30 (13%) |
13/30* (43%) |
18/30* (60%) |
|
| Basal Cell Metaplasia |
3/33 (9%) |
19/30* (63%) |
30/31* (97%) |
2/29 (7%) |
26/30* (87%) |
25/26* (96%) |
0/30 (0%) |
30/30* (100%) |
29/30* (97%) |
|
| Squamous Metaplasia3 |
1/33 (3%) |
11/30* (37%) |
7/31* (23%) |
0/29 (0%) |
16/30* (53%) |
12/26* (46%) |
0/30 (0%) |
24/30* (80%) |
14/30* (47%) |
|
| Atypical Hyperplasia |
0/33 (0%) |
3/30 (10%) |
14/31* (45%) |
0/29 (0%) |
9/30* (30%) |
14/26* (54%) |
0/30 (0%) |
15/30* (50%) |
18/30* (60%) |
|
| Carcinoma | 0/33 (0%) |
2/30 (7%) |
5/31 (16%) |
0/29 (0%) |
7/30* (23%) |
9/26* (35%) |
0/30 (0%) |
10/30* (33%) |
12/30* (40%) |
|
| Sarcoma | 0/33 (0%) |
0/30 (0%) |
1/31 (3%) |
0/29 (0%) |
1/30 (3%) |
0/26 (0%) |
0/30 (0%) |
2/30 (7%) |
0/30 (0%) |
|
| SIX1 IHC | ||||||||||
| Vagina | Epithelium | 33/33 (100%) |
30/30 (100%) |
31/31 (100%) |
29/29 (100%) |
30/30 (100%) |
26/26 (100%) |
30/30 (100%) |
30/30 (100%) |
30/30 (100%) |
| Average SIX1 severity index4 |
2.2 | 1.8 | 1.5 | 1.6 | 1.1 | 1.2 | 1.9 | 1.7 | 1.7 | |
| Uterus | Nonneoplastic Glands5 |
3/33 (9%) |
21/30* (70%) |
30/31* (97%) |
2/29 (7%) |
26/30* (87%) |
25/26* (96%) |
0/30 (0%) |
30/30* (100%) |
30/30* (100%) |
| Average SIX1 severity index4 |
0.1 | 0.9 | 1.5 | 0.1 | 1.5 | 2.0 | 0.0 | 2.0 | 2.6 | |
| Neoplastic Glands6 |
na | 2/2 (100%) |
5/5 (100%) |
na | 7/7 (100%) |
9/9 (100%) |
na | 10/10 (100%) |
12/12 (100%) |
|
| Average SIX1 severity index4 |
na | 2.5 | 2.8 | na | 2.0 | 2.7 | na | 2.1 | 2.4 | |
Statistically significant using one-tailed Fisher’s Exact Test p<0.05 compared to corresponding age-matched CON mice.
n=26–33 mice per treatment and age group as indicated in the table.
Mice were given injections of GEN (50 mg/kg/day) or DES (1 mg/kg/day) on days 1–5 of life.
Mice were necropsied at indicated ages.
Stratified squamous cells in place of glandular epithelium; distinct from single layer of basal cells underlying luminal glandular cells.
Average qualitative severity score from 0 to 4+ for SIX1 immunolabeling across the group.
Number of animals with SIX1-positive immunolabeling out of all animals within that group.
Number of animals with SIX1-positive immunolabeling in neoplastic lesions out of animals with carcinoma.